IT1164244B - Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico - Google Patents

Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico

Info

Publication number
IT1164244B
IT1164244B IT21289/83A IT2128983A IT1164244B IT 1164244 B IT1164244 B IT 1164244B IT 21289/83 A IT21289/83 A IT 21289/83A IT 2128983 A IT2128983 A IT 2128983A IT 1164244 B IT1164244 B IT 1164244B
Authority
IT
Italy
Prior art keywords
pharmaceutical composition
composition containing
therapeutic use
detoxified endotoxin
endotoxin part
Prior art date
Application number
IT21289/83A
Other languages
English (en)
Other versions
IT8321289A0 (it
Inventor
Edgar Ernst Ribi
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of IT8321289A0 publication Critical patent/IT8321289A0/it
Application granted granted Critical
Publication of IT1164244B publication Critical patent/IT1164244B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IT21289/83A 1982-05-26 1983-05-25 Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico IT1164244B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/382,406 US4435386A (en) 1982-05-26 1982-05-26 Refined detoxified endotoxin product

Publications (2)

Publication Number Publication Date
IT8321289A0 IT8321289A0 (it) 1983-05-25
IT1164244B true IT1164244B (it) 1987-04-08

Family

ID=23508812

Family Applications (1)

Application Number Title Priority Date Filing Date
IT21289/83A IT1164244B (it) 1982-05-26 1983-05-25 Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico

Country Status (7)

Country Link
US (1) US4435386A (it)
JP (1) JPS58222027A (it)
CA (1) CA1225591A (it)
DE (1) DE3318568C2 (it)
FR (1) FR2527444B1 (it)
GB (1) GB2122084B (it)
IT (1) IT1164244B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
US4497730A (en) * 1984-04-03 1985-02-05 The United States Of America As Represented By The Department Of Health And Human Services Method for obtaining periplasmic proteins from bacterial cells using chloroform
NL8401226A (nl) * 1984-04-16 1985-11-18 Univ Utrecht Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4845036A (en) * 1987-02-03 1989-07-04 The United States Of America As Represented By The Department Of Health And Human Services Process for isolation of the B oligomer of pertussis toxin
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998035665A1 (fr) * 1997-02-14 1998-08-20 Ajinomoto Co., Inc. Antagonistes des endotoxines
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
NZ584715A (en) 2002-07-15 2011-12-22 Univ Texas Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
WO2008094183A2 (en) * 2006-07-11 2008-08-07 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015042373A1 (en) 2013-09-19 2015-03-26 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
DK3107568T3 (da) 2014-02-20 2024-06-03 Vaxart Inc Formuleringer til indgivelse til tyndtarmen
CN118045170A (zh) 2015-06-12 2024-05-17 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
MX2018010586A (es) 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
JP7146732B2 (ja) 2016-07-13 2022-10-04 オハイオ ステート イノベーション ファウンデーション 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Also Published As

Publication number Publication date
US4435386A (en) 1984-03-06
FR2527444B1 (fr) 1987-02-20
IT8321289A0 (it) 1983-05-25
GB2122084A (en) 1984-01-11
JPS58222027A (ja) 1983-12-23
JPS6234730B2 (it) 1987-07-28
GB8313054D0 (en) 1983-06-15
GB2122084B (en) 1986-02-05
CA1225591A (en) 1987-08-18
DE3318568A1 (de) 1984-01-12
FR2527444A1 (fr) 1983-12-02
DE3318568C2 (de) 1987-01-15

Similar Documents

Publication Publication Date Title
IT1164244B (it) Composizione farmaceutica contenente almeno in parte endotossina detossificata e suo impiego terapeutico
IT1164243B (it) Composizione farmaceutica contenente almeno in parte quantitativi terapeuticamente efficaci di endotossina detossificata raffinata ed il suo impiego terapeutico
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
SE8302774L (sv) Raffinerad, detoxifierad endotoxinprodukt samt sett att framstella detsamma jemte en terapeutisk komposition som innehaller produkten
IT8419266A0 (it) Tessuti del corpo umano e dispositivo per generare calore in procedimento di generazione dicalore, particolarmente per la cura di tumori.
IT7968574A0 (it) Dispositivo di infusione impiantabile nel corpo del paziente
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
MY112405A (en) Method of tumer treatment.
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
WO1992002240A3 (en) Novel methods and compositions for treatment of angiogenic diseases
ES512992A0 (es) "aparato para el tratamiento del cabello y del cuero cabelludo".
NL186432B (nl) Inrichting voor therapie met hoogfrequente straling.
EG15007A (en) Device for the proplylact ic ore therapeutic treatment of cattle
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
SG45366A1 (en) Method of treating and/or diagonising soft tissue tumors
KR890700353A (ko) 면역독소의 면역억제 기저 사람치료법
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
EP0285906A3 (en) Active agent for combating tumours
GR880100589A (en) Metalloporfyrines for the inversion of the toxic activity for the tumors treatment
SU1104709A1 (ru) Эндостат дл внутриполостной лучевой терапии
Edsmyr CHAIRMAN'S SUMMARY